Product
ixabepilone
Name
IXEMPRA
INN Name
ixabepilone
FDA Approved
Yes
2 clinical trials
1 organization
1 indication
1 document
Indication
Breast CancerClinical trial
Randomized, Open Label, Multicentric Phase III Evaluating the Benefit of a Sequential Regimen Associating FEC 100 and Ixabepilone in Adjuvant Treatment of Non Metastatic, Poor Prognosis Breast Cancer Defined as Triple-negative Tumor [HER2 Negative - ER Negative - PR Negative] or [HER2 Negative and PR Negative] Tumor; in Node Positive or Node Negative Patients.Status: Completed, Estimated PCD: 2017-06-01
Clinical trial
Phase I/II Study of Ixabepilone in Combination With the Autophagy Inhibitor Hydroxychloroquine for the Treatment of Patients With Metastatic Breast CancerStatus: Terminated, Estimated PCD: 2011-12-01
Document
DailyMed Label: IXEMPRAOrganization
R-Pharm US Operating, LLC